日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma

新辅助三联免疫检查点阻断疗法治疗新诊断的胶质母细胞瘤

Georgina V Long ,Elena Shklovskaya ,Laveniya Satgunaseelan ,Yizhe Mao ,Inês Pires da Silva ,Kristen A Perry ,Russell J Diefenbach ,Tuba N Gide ,Brindha Shivalingam ,Michael E Buckland ,Maria Gonzalez ,Nicole Caixeiro ,Ismael A Vergara ,Xinyu Bai ,Robert V Rawson ,Edward Hsiao ,Umaimainthan Palendira ,Tri Giang Phan ,Alexander M Menzies ,Matteo S Carlino ,Camelia Quek ,Sean M Grimmond ,Joseph H A Vissers ,Dannel Yeo ,John E J Rasko ,Mustafa Khasraw ,Bart Neyns ,David A Reardon ,David M Ashley ,Helen Wheeler ,Michael Back ,Richard A Scolyer ,James Drummond ,James S Wilmott ,Helen Rizos

Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1+ Myeloid Dendritic Cells

溶瘤性单纯疱疹病毒1型诱导免疫原性细胞死亡,导致BDCA-1+髓系树突状细胞成熟

Philipp Kalus ,Jolien De Munck ,Sarah Vanbellingen ,Laura Carreer ,Thessa Laeremans ,Katrijn Broos ,Inès Dufait ,Julia K Schwarze ,Ivan Van Riet ,Bart Neyns ,Karine Breckpot ,Joeri L Aerts

Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial

低剂量 Nivolumab 联合或不联合 Ipilimumab 作为黑色素瘤转移切除术后的辅助治疗:一项序贯双队列 II 期临床试验

Julia Katharina Schwarze, Soizic Garaud, Yanina J L Jansen, Gil Awada, Valérie Vandersleyen, Jens Tijtgat, Alexandre de Wind, Paulus Kristanto, Teofila Seremet, Karen Willard-Gallo, Bart Neyns

TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma

TriMix 和肿瘤抗原 mRNA 电穿孔树突状细胞疫苗接种加伊匹单抗:晚期黑色素瘤中 T 细胞活化与临床反应之间的联系

Brenda De Keersmaecker, Sofie Claerhout, Javier Carrasco, Isabelle Bar, Jurgen Corthals, Sofie Wilgenhof, Bart Neyns, Kris Thielemans

Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion

接受 VEGFR 抑制剂阿昔替尼治疗的复发性胶质母细胞瘤患者的病情进展与调节性 T 细胞数量增加和 T 细胞耗竭有关

Stephanie Du Four, Sarah K Maenhout, Daphné Benteyn, Brenda De Keersmaecker, Johnny Duerinck, Kris Thielemans, Bart Neyns, Joeri L Aerts

Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma

浆细胞样树突状细胞和髓系抑制细胞在黑色素瘤中的临床意义

Ines Chevolet, Reinhart Speeckaert, Max Schreuer, Bart Neyns, Olga Krysko, Claus Bachert, Mireille Van Gele, Nanja van Geel, Lieve Brochez

Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model

阿昔替尼增加小鼠颅内黑色素瘤模型中免疫细胞的浸润并降低单核细胞 MDSC 的抑制能力

Stephanie Du Four, Sarah K Maenhout, Kari De Pierre, Dries Renmans, Simone P Niclou, Kris Thielemans, Bart Neyns, Joeri L Aerts

Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens

用呈递全长肿瘤抗原的树突状细胞治疗后,对抗原特异性 T 细胞进行表位和 HLA 型独立监测

An M T Van Nuffel, Sandra Tuyaerts, Daphné Benteyn, Sofie Wilgenhof, Jurgen Corthals, Carlo Heirman, Bart Neyns, Kris Thielemans, Aude Bonehill